Exact Mass: 157.0505672

3-Methylcrotonylglycine is an acyl glycine. Acyl glycines are normally minor metabolites of fatty acids. However, the excretion of certain acyl glycines is increased in several inborn errors of metabolism. In certain cases the measurement of these metabolites in body fluids can be used to diagnose disorders associated with mitochondrial fatty acid beta-oxidation. Acyl glycines are produced through the action of glycine N-acyltransferase (EC 2.3.1.13) which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine < -- > CoA + N-acylglycine. 3-Methylcrotonylglycine is a normal amino acid metabolite found in urine. Increased levels of this metabolite are found in patients suffering from leucine catabolic disorders, such as 3-methylcrotonyl-CoA carboxylase deficiency. 3-Methylcrotonylglycine is often considered to be a diagnostic marker of organic acidemias (PMID 11170888). Moreover, 3-methylcrotonylglycine is found to be associated with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency and propionic acidemia, which are also inborn errors of metabolism. 3-Methylcrotonylglycine is an acyl glycine. Acyl glycines are normally minor metabolites of fatty acids. However, the excretion of certain acyl glycines is increased in several inborn errors of metabolism. In certain cases the measurement of these metabolites in body fluids can be used to diagnose disorders associated with mitochondrial fatty acid beta-oxidation. Acyl glycines are produced through the action of glycine N-acyltransferase (EC 2.3.1.13) which is an enzyme that catalyzes the chemical reaction: 3-Methylcrotonylglycine is an acyl glycine, a normal amino acid metabolite found in urine.

2-Aminomuconic acid

(2Z,4E)-5-aminohexa-2,4-dienedioic acid

2-Aminomuconic acid is a product of the Tryptophan metabolism degradation pathway (kinurenine pathway), in a reaction catabolized by the enzyme aminocarboxymuconate semialdehyde decarboxylase [EC:4.1.1.45]. The kynurenine pathway is the major route of L-tryptophan degradation in mammals. (BioCyc) [HMDB] 2-Aminomuconic acid is a product of the Tryptophan metabolism degradation pathway (kinurenine pathway), in a reaction catabolized by the enzyme aminocarboxymuconate semialdehyde decarboxylase [EC:4.1.1.45]. The kynurenine pathway is the major route of L-tryptophan degradation in mammals. (BioCyc).

Paramethadione

5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione

Paramethadione is only found in individuals that have used or taken this drug. It is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.Dione anticonvulsants such as paramethadione reduce T-type calcium currents in thalamic neurons (including thalamic relay neurons). This inhibits corticothalamic transmission and raises the threshold for repetitive activity in the thalamus. This results in a dampening of the abnormal thalamocortical rhythmicity proposed to underlie the 3-Hz spike-and-wave discharge seen on electroencephalogram (EEG) during absence seizures. N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AC - Oxazolidine derivatives C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent

Furaspor

Furan,2-(methoxymethyl)-5-nitro-

1-nitrosonaphthalene

1-Nitrosonaphthalene

C10H7NO (157.0527612)

1-nitrosonaphthalene is considered to be practically insoluble (in water) and basic

Clavam-2-carboxylate

Hydroxyethylclavam

3-(2-hydroxyethyl)-4-oxa-1-azabicyclo[3.2.0]heptan-7-one

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams

ETHADIONE

3-ethyl-5,5-dimethyl-1,3-oxazolidine-2,4-dione

N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AC - Oxazolidine derivatives

Tiglylglycine

2-[(2E)-2-methylbut-2-enamido]acetic acid

Tiglylglycine is an acyl glycine. Acyl glycines are normally minor metabolites of fatty acids. However, the excretion of certain acyl glycines is increased in several inborn errors of metabolism. In certain cases the measurement of these metabolites in body fluids can be used to diagnose disorders associated with mitochondrial fatty acid beta-oxidation. Acyl glycines are produced through the action of glycine N-acyltransferase (EC 2.3.1.13) which is an enzyme that catalyzes the chemical reaction: acyl-CoA + glycine < -- > CoA + N-acylglycine. Tiglylglycine is an intermediate product of the catabolism of isoleucine. An elevated level of tiglylglycine is identified in urine of patients with beta-ketothiolase deficiency or with disorders of propionate metabolism (PMID 7923765). Tiglyglycine is a biomarker for the consumption of cheese. Tiglylglycine is an acyl glycine. Acyl glycines are normally minor metabolites of fatty acids. However, the excretion of certain acyl glycines is increased in several inborn errors of metabolism. In certain cases the measurement of these metabolites in body fluids can be used to diagnose disorders associated with mitochondrial fatty acid beta-oxidation. Acyl glycines are produced through the action of glycine N-acyltransferase (EC 2.3.1.13) which is an enzyme that catalyzes the chemical reaction:

N-Acetylproline

(2S)-1-Acetylpyrrolidine-2-carboxylic acid

N-Acetyl-L-proline or N-Acetylproline, belongs to the class of organic compounds known as N-acyl-alpha amino acids. N-acyl-alpha amino acids are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom. N-Acetylproline can also be classified as an alpha amino acid or a derivatized alpha amino acid. Technically, N-Acetylproline is a biologically available N-terminal capped form of the proteinogenic alpha amino acid L-proline. N-acetyl amino acids can be produced either via direct synthesis of specific N-acetyltransferases or via the proteolytic degradation of N-acetylated proteins by specific hydrolases. N-terminal acetylation of proteins is a widespread and highly conserved process in eukaryotes that is involved in protection and stability of proteins (PMID: 16465618). About 85\\% of all human proteins and 68\\% of all yeast proteins are acetylated at their N-terminus (PMID: 21750686). Several proteins from prokaryotes and archaea are also modified by N-terminal acetylation. The majority of eukaryotic N-terminal-acetylation reactions occur through N-acetyltransferase enzymes or NAT‚Äôs (PMID: 30054468). These enzymes consist of three main oligomeric complexes NatA, NatB, and NatC, which are composed of at least a unique catalytic subunit and one unique ribosomal anchor. The substrate specificities of different NAT enzymes are mainly determined by the identities of the first two N-terminal residues of the target protein. The human NatA complex co-translationally acetylates N-termini that bear a small amino acid (A, S, T, C, and occasionally V and G) (PMID: 30054468). NatA also exists in a monomeric state and can post-translationally acetylate acidic N-termini residues (D-, E-). NatB and NatC acetylate N-terminal methionine with further specificity determined by the identity of the second amino acid. N-acetylated amino acids, such as N-acetylproline can be released by an N-acylpeptide hydrolase from peptides generated by proteolytic degradation (PMID: 16465618). In addition to the NAT enzymes and protein-based acetylation, N-acetylation of free proline can also occur. Many N-acetylamino acids, including N-acetylproline are classified as uremic toxins if present in high abundance in the serum or plasma (PMID: 26317986; PMID: 20613759). Uremic toxins are a diverse group of endogenously produced molecules that, if not properly cleared or eliminated by the kidneys, can cause kidney damage, cardiovascular disease and neurological deficits (PMID: 18287557).

1-Acetylproline

1-acetylpyrrolidine-2-carboxylic acid

1,2,3-Triazine, 4-phenyl-

C9H7N3 (157.0639942)

Succinimidyl acetate

2,5-dioxopyrrolidin-1-yl acetate

2-(Methylsulfonyl)pyridine

2-(Methylsulphonyl)pyridine

2-Phenyl-1,3,5-triazine

C9H7N3 (157.0639942)

5-Diazo-4-oxo-L-norvaline

2-amino-5-diazo-4-oxopentanoic acid

C5H7N3O3 (157.0487392)

1-Methyl-5-nitro-1H-imidazole-2-methanol

(1-methyl-5-nitro-1H-imidazol-2-yl)methanol

C5H7N3O3 (157.0487392)

Glycine, N-[(2E)-2-methyl-1-oxo-2-butenyl]-

Benzenesulfonamide

Benzenesulfonamide monosodium salt

C5H4FN3O2 (157.02875360000002)

D004791 - Enzyme Inhibitors > D002257 - Carbonic Anhydrase Inhibitors

Favipiravir

6-Fluoro-3-hydroxy-2-pyrazinecarboxamide

J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C471 - Enzyme Inhibitor > C25995 - RNA Polymerase Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

(2S)-1,2-Dimethyl-3,4-dioxoazetidine-2-carboxylic acid

2-Aminomuconic acid

The 2-amino derivative of muconic acid.

2-Amino-4-hydroxy-6-heptynoic acid

BENZENESULFONAMIDE

D004791 - Enzyme Inhibitors > D002257 - Carbonic Anhydrase Inhibitors CONFIDENCE standard compound; EAWAG_UCHEM_ID 3595

936-05-0

C5H7N3O3 (157.0487392)

MCULE-2784569067

N-methylbenzylamine hydrochloride

Quaternary ammonium compounds, benzylbis(hydrogenated tallow alkyl)methyl, chlorides

C8H12ClN (157.06582219999999)

3-Methyl-Delta2-dihydromuconsaeure-1-amid|5-carbamoyl-4-methyl-pent-4-enoic acid|5-Carbamoyl-4-methyl-pent-4-ensaeure

4,5-Dihydro-furo[3,4-d][1,3]thiazin-7-one

(2S,1S,2S)-2-(2-hydroxy-3-cyclopentenyl)glycine

3-Acetylamino-3,4-dihydro-4-methyl-2(5H)-furanone

Plicatanin A

5-Oxo-2(5H)-isoxazolepropanoic acid

Ethyl 5-oxo-DL-prolinate

Quinoline-4-carbaldehyde

C10H7NO (157.0527612)

2-(2,5-dioxopyrrolidin-3-yl)acetic acid

2-Amino-2,4-hexadienedioic acid

Methyl 6-oxopiperidine-2-carboxylate

Tiglylglycine

N-Tigloylglycine